• EMA Validates Application for Tepotinib for Advanced NSCLC americanpharmaceuticalreview
    December 14, 2020
    Merck announced the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor gene ...
PharmaSources Customer Service